Table II.
Comparison between the 2 studied groups according to outcome and adverse events
| Parameter | Group A (n = 200) | Group B (n = 200) | χ2 | P-value | |
|---|---|---|---|---|---|
| Outcome | |||||
| Urea breath test: | |||||
| Success rate | 172 (86%) | 149 (74.5%) | 8.344* | 0.004* | |
| Failure rate | 28 (14%) | 51 (25.5%) | |||
| Adverse events: | |||||
| Diarrhoea | 8 (4%) | 11 (5.5%) | 0.497 | 0.481 | |
| Vomiting/nausea | 7 (3.5%) | 13 (6.5%) | 1.895 | 0.169 | |
| Constipation | 4 (2%) | 7 (3.5%) | 0.841 | 0.359 | |
| Abdominal bloating | 7 (3.5%) | 7 (3.5%) | 0.000 | 1.000 | |
| Abdominal pain | 7 (3.5%) | 6 (3%) | 0.080 | 0.778 | |
| Taste disturbance | 5 (2.5%) | 9 (4.5%) | 1.184 | 0.276 | |
| Stomatitis | 4 (2%) | 7 (3.5%) | 0.841 | 0.359 | |
| Rash | 4 (2%) | 10 (5%) | 2.665 | 0.103 | |
χ2 – Chi-square test, p – p-value for comparing between the studied groups. *Statistically significant at p ≤ 0.05. Group A – vonoprazan-based regimen, Group B – PPI-based regimen.